Kerry Wentworth - Flexion Therapeutics Chief Regulatory Officer
Executive
Ms. Kerry Wentworth is a Chief Regulatory Officer of the FLEXION THERAPEUTICS, INC. Ms. Wentworth was appointed as our Chief Regulatory Officer in December 2017 and was previously our Senior Vice President of Regulatory Affairs Quality. Prior to joining us in 2014, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts for nearly 10 years. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc., where she was responsible for advancing their lead program through Phase 3 development and into the registration phase with FDA and EMA. Ms. Wentworth also held positions of increasing responsibility within Regulatory Affairs at Genzyme since 2017.
| Age | 45 |
| Tenure | 7 years |
| Phone | 781 305-7777 |
| Web | www.flexiontherapeutics.com |
Flexion Therapeutics Management Efficiency
The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 228.9 M in liabilities. Flexion Therapeutics has a current ratio of 4.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Flexion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Flexion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Flexion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Flexion to invest in growth at high rates of return. When we think about Flexion Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Maya Leibman | American Airlines Group | 52 | |
| Daniel Cravens | American Airlines Group | N/A | |
| Mecole Brown | American Airlines Group | N/A | |
| Brian Krakower | BJs Restaurants | 53 | |
| Bradford Holt | Mesa Air Group | 64 | |
| Paul Galloway | American Airlines Group | N/A | |
| Ronald Defeo | American Airlines Group | N/A | |
| Amy Krallman | BJs Restaurants | 57 | |
| Putnam Shin | BJs Restaurants | 45 | |
| Michael Oriolo | Shake Shack | N/A | |
| John Allegretto | BJs Restaurants | 51 | |
| Priya Aiyar | American Airlines Group | 49 | |
| Jacob Guild | BJs Restaurants | N/A | |
| Aurimas Sanikovas | American Airlines Group | 39 | |
| Vasu Raja | American Airlines Group | 47 | |
| Shake Shack | Shake Shack | N/A | |
| Beverly Goulet | American Airlines Group | 60 | |
| Jacek Tucharz | American Airlines Group | 45 | |
| Esq Palmese | Shake Shack | 45 | |
| Michael Ferverda | Mesa Air Group | 80 | |
| Spero Alex | The Cheesecake Factory | N/A | |
Management Performance
| Return On Asset | -18.99 |
Flexion Therapeutics Leadership Team
Elected by the shareholders, the Flexion Therapeutics' board of directors comprises two types of representatives: Flexion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flexion. The board's role is to monitor Flexion Therapeutics' management team and ensure that shareholders' interests are well served. Flexion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flexion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Sandesh Mahatme, Director | ||
| Scott Canute, Director | ||
| Mark Levine, Senior Vice President General Counsel, Secretary | ||
| Kerry Wentworth, Chief Regulatory Officer | ||
| Dan Thornton, Vice President - Market Access | ||
| John Magee, Vice President - Sales | ||
| Neil Bodick, Chief Medical Officer & Co-Founder | ||
| Mark Fraga, Vice President - Marketing | ||
| Michael Clayman, CEO, Co-Founder, Board Member | ||
| Ann Merrifield, Director | ||
| Alan Milinazzo, Independent Director | ||
| Jon Mahlowitz, VP of Legal Affairs | ||
| Frederick Driscoll, CFO and Principal Accounting Officer | ||
| Heath Lukatch, Independent Director | ||
| Christina Willwerth, Chief Strategy Officer | ||
| Patrick Mahaffy, Chairman of the Board | ||
| Samuel Colella, Independent Director | ||
| Yamo Deniz, Chief Medical Officer | ||
| Mark Stejbach, Director | ||
| Scott Kelley, Vice President - Medical Affairs |
Flexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flexion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -18.99 | |||
| Profit Margin | (92.52) % | |||
| Operating Margin | (71.24) % | |||
| Current Valuation | 408.79 M | |||
| Shares Outstanding | 49.94 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 92.20 % | |||
| Number Of Shares Shorted | 5.67 M | |||
| Price To Earning | (8.29) X | |||
| Price To Book | 35.88 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |